Powerful Investigation: Abortion Pill Dangers Unveiled

A silhouette of a woman sitting on the floor, looking contemplative near a window

Senator Josh Hawley just launched a powerful investigation into abortion pill makers, exposing grave risks to women’s health and creating a hotline for victims—finally holding Big Pharma accountable for profiting off danger.

Story Highlights

Hawley demands documents from Danco Laboratories and GenBioPro on hemorrhage, infection, sepsis risks by April 24.
Accompanies Safeguarding Women from Chemical Abortion Act to revoke FDA approval and enable lawsuits against manufacturers.
EPPC research reveals 11% serious adverse events—22 times higher than FDA’s label—prompting HHS review.
Press conference featured women harmed by mifepristone, underscoring real dangers amid telehealth expansion.
Actions protect families and conservative values by prioritizing women’s safety over abortion industry profits.

Hawley’s Investigation Targets Abortion Pill Risks

Senator Josh Hawley, chair of the Senate Judiciary Subcommittee on Crime and Counterterrorism, sent letters on March 19, 2026, to Danco Laboratories and GenBioPro. These companies manufacture mifepristone, the primary chemical abortion drug. Hawley requires documents on adverse events, internal risk knowledge including hemorrhage, infection, and sepsis, plus regulator communications by April 24. This probe addresses claims that firms profit billions despite known dangers to women.

Recent Bill Seeks to Revoke FDA Approval

On March 11, 2026, Hawley introduced the Safeguarding Women from Chemical Abortion Act. The legislation bans mifepristone for abortions, revokes FDA approval granted in 2000, and allows lawsuits against manufacturers. Representative Diana Harshbarger announced a companion bill in the House. A press conference that day included testimonies from women harmed by the drug and pro-life leaders, highlighting personal tragedies from its use.

Background on Mifepristone Safety Debates

Mifepristone, used in 63% of U.S. abortions in 2023, saw expanded telehealth access after the 2022 Dobbs decision. An April EPPC paper claimed 11% serious adverse events—22 times the FDA’s under 0.5% label—prompting HHS Secretary Robert F. Kennedy Jr. to call findings alarming and order a review. Critics like Plan C’s Elisa Wells dispute this as bogus science, but victim stories fuel GOP pushback against lax oversight.

Hawley’s May 2025 bill sought FDA safeguards and telehealth lawsuits. State efforts advance, like South Dakota and Kentucky treating pills as controlled substances. The 2023 Supreme Court upheld FDA approval, but post-Dobbs shifts regulation to states, amplifying federal scrutiny.

Josh Hawley opens investigation into abortion pill companies, creates hotline for victimshttps://t.co/HhqYAohTlg #News #JoshHawley #Abortion #ProLife

— Replaye (@ItsReplaye) March 24, 2026

Potential Impacts and Stakeholder Reactions

Short-term, demanded documents could expose non-disclosures, spurring FDA changes or lawsuits. Long-term, a ban disrupts medication abortions, shifting to surgical methods or state rules, while empowering private actions against makers. Manufacturers face revenue hits; pro-life groups gain momentum protecting unborn life and maternal health.

Hawley states the drug is inherently dangerous, demanding congressional action. RFK Jr. echoes alarm over risks. This tests Trump administration dynamics amid veto threats on national bans, yet energizes conservatives frustrated with government overreach in health policy.